Enzene Biosciences Ltd launched the NeX™ partnership model for a conventional fed-batch biologics facility, bringing capital costs down to roughly $60-80M using EnzeneX and Enzene technology transfer support.

We Are Enzene, a Continuously Innovative Development and Manufacturing (CIDMO) partner to innovators and biosimilar developers. From state-of-the-art sites in Pune, India, and Hopewell, New Jersey, we provide fully-integrated services that span discovery, development, and commercial supply. Our innovative EnzeneX™ platform incorporates the first truly fully-connected continuous manufacturing™ (FCCM™) technology to be validated for commercial biologics supply. We are proud pioneers of next-generation biologics technologies, and disruptors of existing biologics manufacturing paradigms: accelerating time-to-market and providing the highest production yields to drive down the cost of a broad range of biologic modalities. For more information on Enzene, please visit www.enzene.com